# Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder

> **NCT00733668** · PHASE2 · COMPLETED · sponsor: **AstraZeneca**

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Quetiapine fumarate (Seroquel)

## Key facts

- **NCT ID:** NCT00733668
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** — (—)
- **Last updated:** 2009-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00733668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00733668, "Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00733668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*